The oncology therapeutics developer has added $66m to its coffers thanks to investors including Berkeley Catalyst Fund.
Circle Pharma, a US-based oncology therapeutics spinout of University of California (UC), San Francisco and Santa Cruz, picked up $66m in series C financing on Wednesday backed by UC Berkeley’s investment vehicle, Berkeley Catalyst Fund.
Column Group and Nextech Invest co-led the round, which also attracted pharmaceutical firms Eli Lilly and ShangPharma as well as Pandect Bioventures, Euclidean Capital, Pavillion Capital, Hartford HealthCare Endowment and LifeForce Capital.
Circle Pharma is working on a macrocycle drug discovery and development…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
